8th Dermatology Drug Development Summit

The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion, as Johnson & Johnson make a $3.35B play for bispecific candidates, Alumis secured $259M series C and Galderma, Incyte, and Eli Lilly unveil late-breaking data.

With a fast-evolving drug development landscape, remaining at the forefront of promising targets is now more crucial than ever. That's why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston, MA), the definitive industry-led forum uniting 130+ large pharma, biotech, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease.

Explore the end-to-end conference program here: https://ter.li/itjpi2

Featuring 35+ expert speakers from the likes of Alys Pharmaceuticals, LEO Pharma, Incyte and AbbVie, program highlights include:

2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy, providing more depth of content supporting disease pathogenesis understandings and novel target validation, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges
4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa, JAK Inhibitors and Assets Targeting Multiple Indications, plus laying foundations for Recruitment and Retention finesse.
Increased drug development landscape visibility, including clinical case studies from early to late-stage programs, all with dedicated Q&A time, for Monoclonal Antibodies, Oral and Topical Small Molecules, Oral Peptides, siRNA Lipid Conjugates, Bispecific Antibodies and more!